Overview

Aequita Bioworks uses artificial intelligence and machine learning to speed up drug discovery by analyzing complex biological data with a computational platform. This in silico approach moves tasks that used to require months in the lab into data-center simulations. The company develops its own drug candidates and may partner with pharmaceutical companies to apply its platform to their pipelines. Its initial focus targets muscle loss linked to GLP-1 medications, using simulations to model biological systems and offload significant laboratory work to the silicon platform. Revenue is expected from progressing proprietary drug candidates through clinical stages or through licensing and collaboration agreements with other life sciences players. Overall, the goal is to shorten development timelines and reduce costs in the biopharma discovery process while building a pipeline of drug candidates and/or deepening partnerships that leverage its AI-driven platform.